MedTrace Logo

Nebulized Hypertonic Saline for Bronchiolitis

NCT00619918 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 447

Last updated 2024-11-05

Study results available
· View outcomes & findings →

Summary

This study aims to examine the effect of nebulized 3% hypertonic saline in the treatment of viral bronchiolitis. The investigators hypothesize that nebulized 3% saline will decrease rate of hospital admission, decrease clinical severity scores, and decrease length of stay.

Conditions

  • Bronchiolitis

Interventions

DRUG

Nebulized 3% saline

4 ml inhaled q8h

DRUG

Nebulized 0.9% saline

normal saline

Sponsors & Collaborators

Principal Investigators

  • Susan Wu, MD · Childrens Hospital Los Angeles/University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2011-05-31
Completion
2011-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00619918 on ClinicalTrials.gov